Many theories try to explain cardioprotection from SGLT2 inhibition via different effects, that is, blood pressure lowering, diuresis/natriuresis increase, hyperuricemia reduction, glucose and weight loss control, epicardial fat mass decrease, vascular function improvement, oxidative stress and inflammation decrease, cardiac energy metabolism improvement, and adverse cardiac remodeling prevention, as exhaustively discussed in a recent report (Lopaschuk and Verma, 2020). The gene discussed is SLC5A2; the disease is hyperuricemia.